Skip to main content
Sign In

About the Program

                        Thomas L. Petty Aspen Lung Conference

                                        61st Annual Meeting
           "Translating Resilience and Pathogenesis to Personalized Therapy for COPD”                                           Irina Petrache, M.D., Chair                                                                    R. William Vandivier, M.D., Chair                                                                  Moumita Ghosh, Ph.D., Co-Chair                                                                         June 6-9, 2018                                                                      The Gant Conference Center, Aspen, Colorado                                                              

Chronic obstructive pulmonary disease (COPD) is the 3rd leading cause of death in the United States and the 4th leading cause of death worldwide.  Despite progress, current therapies only mitigate symptoms and have no clear effect on mortality or the long-term decline in lung function. Understanding the pathophysiology of COPD, developing novel treatment strategies, and effectively implementing lung-reparative therapeutics would be expected to have significant impact on COPD, as well as other pulmonary diseases.  With an emphasis on the integration of basic, translational and clinical approaches, the 61st AnnualThomas L. Petty Aspen Lung Conference will focus on a central question: how can knowledge of resilience or susceptibility to develop COPD be translated into more effective therapies?  To address this central question, we have organized the program into a series of thematic sessions that will be framed by a Keynote Address, Clinical Perspective and NHLBI Perspective. The thematic sessions will focus on (i) clinical and molecular heterogeneity of COPD,  (ii) COPD as a disease of accelerated aging, (iii) stem cell dysfunction and regenerative therapies for COPD, (iv) immune and epithelial cell mechanisms of COPD exacerbations, (v) metabolic and biochemical mechanisms of COPD pathogenesis, and (vi) consequences of COPD beyond the obstructed lung. These thematic sessions will be anchored by state-of-the-art presentations from thought leaders in each respective area, with ample time dedicated to scientific debate.  Finally, the varied scientific themes and therapeutic strategies emerging during the conference will be reconciled in a concluding Conference Summary presented by Stephen I. Rennard, M.D., Professor of Medicine, University of Nebraska and Head, Clinical Discovery Unit, AstraZeneca.

Abstract deadline is February 14, 2018.  For more information, contact: R. William Vandivier, M.D., c/o Jeanne Cleary, Thomas L. Petty Aspen Lung Conference, PO Box 1622, Parker, CO 80134   Phone:  (303) 358-2797.  Fax:  (720) 851-1034.  


 We seek to accomplish the following objectives:

 1.  To provide an international forum for leading basic, translational, and clinical researchers to exchange ideas regarding fundamental concepts underlying susceptibility and resistance to develop COPD.

 2.  To stimulate interactions between the fields of phenotype/endotypes, genomics/epigenetics, aging, stem cell biology, metabolism and lipid biochemistry with the goal of identifying emerging, shared interests that may lead to the performance of more efficient and productive research.

 3.  To advance our understanding of clinical and molecular COPD phenotypes/endotypes that predict risk or response in order to quickly translate preclinical findings to more effective, personalized therapies.

 4. To challenge and thereby stimulate the scientific interests of trainees, attracting a new generation of junior investigators into the field of COPD pathobiology.

 At the conclusion of this conference attendees will be able to:
 1)  Discuss the concept of COPD heterogeneity, and the possibility that unique phenotypes or endotypes may identify cohorts with common mechanisms of disease and response to treatment. 
 2)  Appreciate the complex interactions between genomics/epigenetics, aging, immune/epithelial interactions, metabolism and lipid biochemistry, and their link to COPD susceptibility and resilience.
 3)  Incorporate current concepts from stem cell biology to better understand repair of the injured lung.
 4)  Understand mechanisms by which pulmonary vascular disease and lung cancer develop in COPD.

Intended Audience:  Local/Regional/National/International Physicians/Clinicians (adult and pediatric)/Research Physician-Scientists in Pulmonary Sciences, Critical Care and Sleep Medicine/Primary Care Physicians/General Medicine Physicians/Public Health.

Please indicate if you have any need for auxiliary aids or special assistance services